Chest
Initial Evaluation of the Patient With Lung Cancer*: Symptoms, Signs, Laboratory Tests, and Paraneoplastic Syndromes
Section snippets
Chest Radiography
The chest radiograph plays a pivotal role in the recognition of lung cancer. Certainly, in the asymptomatic patient, an abnormality on the chest radiograph would be the first clue to the presence of lung cancer. In patients with symptoms related to the primary tumor, the chest radiograph may often strongly support a suspicion of carcinoma of the lung. For patients presenting with either nonspecific systemic complaints or symptoms suggestive of metastatic disease, the chest radiograph will be
Symptoms, Signs, and Laboratory Tests in Lung Cancer
Symptoms, signs and abnormalities in laboratory tests relating to the lung cancer can be classified as follows: (1) those related to the primary lesion, (2) those related to intrathoracic spread, (3) those related to distant metastasis, and (4) those related to paraneoplastic syndromes.
Symptoms and Signs Related to the Primary Tumor
The frequencies of local and systemic symptoms in patients with lung cancer are summarized in Table 1. 8910111213
Signs and Symptoms of Intrathoracic Spread
Intrathoracic spread of lung cancer, either by direct extension or lymphatic spread, produces a variety of symptoms and signs. These may be caused by involvement of the following structures: (1) nerves, eg, recurrent laryngeal nerve, phrenic nerve, brachial plexus, and sympathetic nerve trunks; (2) chest wall and pleura; (3) vascular involvement, eg, superior vena cava (SVC), pericardium, and heart; and (4) viscera, including esophagus.
Symptoms, Signs, and Laboratory Tests Indicating Extrathoracic Metastases
Approximately one third of patients present with symptoms as a result of distant metastases. The most common sites of distant metastasis from lung cancer are the bones; liver, adrenal glands, and intraabdominal lymph nodes; brain and spinal cord; and lymph nodes and skin.
Paraneoplastic Syndromes
Paraneoplastic syndromes are a group of clinical disorders associated with malignant diseases that are not directly related to the physical effects of primary or metastatic tumor. The exact mechanism by which paraneoplastic syndromes occur is not fully understood. Paraneoplastic syndromes occur in at least 10% of patients with bronchogenic carcinoma.89
The extent of paraneoplastic symptoms is unrelated to the size of the primary tumor, and in some cases can precede the diagnosis of malignant
Summary
More than 90% of patients with lung cancer will be symptomatic at presentation. A minority present with symptoms related to the primary tumor, and most patients present with either nonspecific systemic symptoms, including anorexia, weight loss and fatigue, or specific symptoms indicating metastatic disease. Prognosis is related to the type of presenting symptoms. Asymptomatic patients and patients with symptoms related to the primary tumor have better 5-year survivals than those with systemic
Summary of Recommendations
- 1.
All patients with known or suspected lung cancer should undergo a thorough history, physical examination, and standard laboratory tests as a screen for metastatic disease. Level of evidence, fair; benefit, substantial; grade of recommendation, B
- 2.
Patients with lung cancer and a paraneoplastic syndrome should not be precluded from potentially curative therapy on the basis of these symptoms alone. Level of evidence, fair; benefit, substantial; grade of recommendation, C
References (54)
Imaging bronchogenic carcinoma
Chest
(2000)Radiographic manifestations of primary bronchogenic carcinoma
Radiol Clin North Am
(1990)Clinical aspects of lung cancer
Semin Roentgenol
(1990)- et al.
Clinical manifestations of lung cancer
Chest
(1974) - et al.
Carcinoma of the lung
Ann Thorac Surg
(1980) - et al.
Diagnostic tests for lung cancer
Mayo Clin Proc
(1993) Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph
Chest
(1997)- et al.
Prognostic value of the superior vena cava syndrome as the presenting sign of small cell anaplastic carcinoma of the lung
Eur J Cancer
(1980) - et al.
Rapid diagnosis of lung cancer from palpable metastases by needle thrust
Chest
(1990) - et al.
Computed tomographic scanning of the brain in the initial staging of bronchogenic carcinoma
Chest
(1984)
The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma
Chest
Staging of non-small cell bronchogenic carcinoma
Chest
Paraneoplastic syndromes associated with lung cancer
Mayo Clin Proc
Plasma arginine vasopressin in the syndrome of antidiuretic hormone excess associated with bronchogenic carcinoma
Am J Med
Ectopic secretion of neurohypophyseal peptides in patients with malignancy
Endocrinol Metab Clin North Am
Ectopic production of lipotropin by cancer
Am J Med
Digital clubbing and hypertrophic osteoarthropathy
Br J Dis Chest
Digital clubbing and lung cancer
Chest
Hypertrophic pulmonary osteoarthropathy
Dis Chest
Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell carcinoma
Lancet
Symptoms, signs and staging of lung cancer
Eur Respir Mon
Lung cancer: perspectives and prospects
Ann Intern Med
Pathology of carcinoma of lung
J Thorac Imaging
The changing histopathology of lung cancer
Cancer
1976 Caldwell Lecture: varying manifestation of peripheral pulmonary neoplasms: a radiologic-pathologic correlative study
AJR Am J Roentgenol
Diagnosis of symptomatic lung cancer
Semin Respir Med
Pretreatment evaluation of non-small-cell lung cancer: The American Thoracic Society and The European Respiratory Society
Am J Respir Crit Care Med
Cited by (178)
Relationships Among Perceived Social Support, Family Resilience, and Caregiver Burden in Lung Cancer Families: A Mediating Model
2023, Seminars in Oncology NursingLongitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data
2022, Clinical Lung CancerCitation Excerpt :Symptoms and toxicities were generally similar between patients with LC-SCLC and ES-SCLC and may partially explain why patients reported similar HUS when commencing first-line systemic therapy, regardless of disease stage. It may be that with SCLC, the dominant driving symptoms associated with HUS are weight loss, fatigue, and symptoms associated with extrathoracic metastases (eg, pain)36 rather than gastrointestinal symptoms. Multivariable analyses identified several clinico-demographic factors associated with lower HUS, including being of extensive stage disease, being female, and having the presence of bone metastasis, progressive disease and/or an ECOG PS ≥ 2.
Lung Cancer Book—Prehabilitation Chapter
2022, Lung Cancer RehabilitationLungNet: A hybrid deep-CNN model for lung cancer diagnosis using CT and wearable sensor-based medical IoT data
2021, Computers in Biology and MedicineEffects of foam pad balance exercises on cancer patients undergoing chemotherapy: A randomized control trial
2021, Journal of Bodywork and Movement Therapies